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Abstract
The proteostasis network includes all the factors that control the function of proteins in their native state and
minimize their non-functional or harmful reactions. The molecular chaperones, the important mediator in the
proteostasis network can be considered as any protein that contributes to proper folding and assembly of other
macromolecules, through maturating of unfolded or partially folded macromolecules, refolding of stress-denatured
proteins, and modifying oligomeric assembly, otherwise it leads to their proteolytic degradation. Viruses that use
the hosts’ gene expression tools and protein synthesis apparatus to survive and replicate, are obviously protected
by such a host chaperone system. This means that many viruses use members of the hosts’ chaperoning system to
infect the target cells, replicate, and spread. During viral infection, increase in endoplasmic reticulum (ER) stress due
to high expression of viral proteins enhances the level of heat shock proteins (HSPs) and induces cell apoptosis or
necrosis. Indeed, evidence suggests that ER stress and the induction of unfolded protein response (UPR) may be a
major aspect of the corona-host virus interaction. In addition, several clinical reports have confirmed the
autoimmune phenomena in COVID-19-patients, and a strong association between this autoimmunity and severe
SARS-CoV-2 infection. Part of such autoimmunity is due to shared epitopes among the virus and host. This article
reviews the proteostasis network and its relationship to the immune system in SARS-CoV-2 infection.
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Introduction
Since 2019, severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) infection, the seventh hu-
man coronavirus infectious disease, has affected about
218 countries and territories and caused the deaths of
hundreds of thousands of people around the world. It
causes coronavirus disease 2019 (COVID-19) with high
rates of infection and severe respiratory disorders char-
acterized by early symptoms of fever, cough, sputum
production, fatigue, and myalgia. SARS-CoV-2 is an
enveloped, positive-sense, single-stranded RNA virus
with a genome of nearly 30,000 nucleotides containing
5′ capped and 3′ polyadenylated. Entry into host cells is
the first step of viral infection that is occurred through
interaction of viral spike glycoprotein and angiotensin-
converting enzyme 2 (ACE2) receptor. High infection of
the virus due to high rate of its proliferation, naturally
leads to mutations in its genome, which, if the host pro-
tein synthesis, maturation and modification systems
work together, leads to more aggressive forms of the
virus and greater resistance [1]. Like other viruses,
SARCE-CoV-2 mutates over time to adapt. Indeed,
thousands of mutations have occurred since the virus
was identified [2]. The genome of RNA viruses is highly
susceptible to random mutations, due to the lack of
proofreading activity in their viral RNA polymerase [3].
The resulting variance in the protein sequence may lead
to changes in the structure and function of the protein
that strengthen viral survival capability, pathogenicity
and epidemics. The survival of the virus despite such
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mutations may due to the involvement of the host pro-
teostasis network [1, 4].
The proteostasis network includes all the factors that
control the function of proteins in their native state and
minimize their non-functional or harmful reactions [5].
Many small proteins can achieve their folding even after
the denaturators have been removed, due to the specific
information sequence in their molecule; but those with
more complex structures or multiple domains or sub-
units require regulators and/or mediators such as chap-
erones to achieve their main folding, otherwise they
enter intracellular digestion processes such as prote-
asome or autophagy systems [6]. Thus, in a virus attack,
on the one hand, the body’s immune system may be
stimulated against the invading agent and chaperone
molecules may have positive effects in this stimulation,
and on the other side, the correcting and chaperoning
molecular system may help the invader to survive. Vi-
ruses themselves do not have molecular chaperones and
must use infected host chaperones [7]. Overexpression
of host chaperones can be beneficial to the virus life
cycle, including virus entry into the host cell, disassem-
bly, activation of viral polymerases, transmission of the
virus genome to the nucleus, as well as synthesis of
structural proteins, the assembly, and the release of viral
particles from the host cell. During these processes, both
the cytoplasmic factor and the endoplasmic reticulum
come into play. However, the capacity of the cell chap-
eroning activity is limited and mass production of viral
proteins in infected host cells induces ER stress due to
the production and accumulation of unfolded and mis-
folded viral proteins. ER stress induces the unfolded pro-
tein response (UPR), a process that aims to restore the
ER homeostasis by suppressing translation and increas-
ing the ER folding capacity, otherwise, disrupted cell
proteosis leads to apoptosis or cell necrosis [7, 8].
It has been proved that bats are a repository for a var-
iety of viruses, including the Ebola viruses, coronaviruses
(CoVs), the Nipah and Hendra viruses [9]. Bats infected
with these viruses are clinically asymptomatic, but these
viruses often cause severe infections and mortality in
mammals. For example, Ebola, a filovirus causes
hemorrhagic disease, and CoVs cause severe acute re-
spiratory syndrome (SARS), Middle East respiratory syn-
drome (MERS), porcine epidemic diarrhea (PED) and
severe acute diarrhea syndrome (SADS). These observa-
tions have allowed researchers to speculate that bats are
the likely reservoirs or ancestral hosts for several viruses.
The reason for bats’ coexistence with viruses without be-
ing severely damaged may be due to new traits that bats
have acquired during evolution. One of the reasons for
bats’ resistance is probably due to the high expression of
heat shock proteins in their various tissues, probably due
to the metabolic stresses induced by high temperatures
generated by their sustained flight, which causes cells to
survive under stress [9, 10]. For example, the elevated
HSP70 binds to and degrades the p65 subunit of NFκB
in such conditions, and inhibits the “cytokine storm”
[11] caused by viral infection such as SARS.
The Proteostasis Network
During synthesis, the protein undergoes a variety of con-
formations until it reaches its most thermodynamically
stable form by creating intramolecular interactions.
Nevertheless, abnormal intramolecular interactions may
occur that are thermodynamically more stable than the
native state, leading to the formation of various species
including oligomers, amorphous aggregates, and amyloid
fibers [12]. The proteostasis network blocks such spon-
taneous interactions during and after translation, which
may lead to problems such as Parkinson’s, Alzheimer’s,
cardiomyopathy, and amyotrophic lateral sclerosis [13].
A proteostasis network consisting of ~ 2000 proteins
in human cells is essential to control the normal state
and functional levels of proteins to minimize potentially
useless reactions or harmful pathways due to deformed
or accumulated proteins [5]. The three arms of this net-
work activity are protein synthesis, folding conform-
ational maintenance and degradation. Different
molecular chaperones cooperate with this network in
folding, refolding and disaggregation reactions [5]. Chap-
erones can be considered as a functionally related group
of proteins that help other macromolecules to achieve
natural folding or proper assembly, under physiological
and stress conditions. If the repair is useless, they lead
the abnormal proteins to the cellular digestive system,
the ubiquitin-proteasome system and the
autophagosome-lysosomal machinery [14, 15]. In
addition to correcting the physical structure of proteins,
they mediate the solubility of misfolded proteins and
prevent their self-association and toxic aggregation.
However, the presence of various factors such as stress,
mutation, heavy metals, reactive oxygen species, transla-
tional deviation or mRNA defect may overshadow cell
repair operations and increase the possibility of abnor-
mal intramolecular and/or intermolecular interactions
[13, 16]. Chaperons typically recognize exposed hydro-
phobic amino acid residues and unstructured polypep-
tide backbones in their substrate proteins, which are
unifying features of non-native conformations and make
hydrophobic and electrostatic interactions with them to
prevent (or reverse) misfolding and aggregation [16]. In
this way, chaperones are similar to enzymes because
they do not enter the structure of their substrate and re-
main intact after playing their role, but unlike enzymes,
they lack an active site and work on a wide range of
substrates.
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In humans, ~ 300 chaperones have been identified that
are metabolically divided into two main groups, ATP-
dependent and non-ATP-dependent. Each group is also
divided into subgroups based on their structure and
function [17]. The cellular expression of some chaper-
ones, known as heat-shock cognates (HSCs), is constitu-
tive in order to perform vital housekeeping functions,
while the expression of others termed as heat-shock pro-
teins (HSPs) is due to existence of a stimulus or stress
such as high heat or other forms of stress [18]. Chap-
erons are indicated by acronyms and the accompanying
number indicates their molecular weight such as small
heat shock proteins (sHSPs), HSP60, HSP70 and HSP90
[19]. HSPs, as their name implies, are produced in re-
sponse to high temperatures, although they are also pro-
duced by other stressful stimuli such as cold. They are
divided into classes of HSP33, HSP60, HSP70/HSP110,
HSP90, HSP100, and the small heat-shock proteins
(sHSPs) [20]. Among them, HSP70 and HSP90 are bet-
ter known and their levels increase during viral infection.
They are able to interact with vital components of both
the innate and adaptive immune systems [21]. Therefore,
some chaperones may have antiviral effects by stimulat-
ing the immune response against the virus. Guihur et al.
suggested that following acute respiratory syndrome
caused by coronavirus, HSP70 increased to minimize al-
veolar lung cell damage, but with the persistence of
fever, chaperones decreased [22]. Therefore, the use of
fever-relievers may enhance chaperones and improve
their function in reducing apoptosis of respiratory cells.
SARS-COV-2, and ER Stress
The severe acute respiratory syndrome coronavirus-2
(SARS-CoV-2), the causative agent of COVID-19
Fig. 1 Spherical shape of coronavirus is characterized by heavily glycosylated spike (S), matrix or membrane (M) and envelope (E) proteins on the
surface, and helical nucleocapsid inside which is formed by binding of the nucleocapsid (N) proteins on the genomic RNA. Receptors: ACE2
(angiotensin converting enzyme) and TMPRSS2 (Transmembrane protease, serine 2)
Khomari et al. Biological Procedures Online            (2021) 23:8 Page 3 of 10
belongs to order Nidovirales, family Coronaviridae, and
subfamily Orthocoronavirinae. Orthocoronavirinae con-
sists of four genera, including Alphacoronavirus (α-
CoV), Betacoronavirus (β-CoV), Gammacoronavirus (γ-
CoV) and Deltacoronavirus (δ-CoV). Clinically, the im-
portant coronaviruses belong to the α-CoVs and β-CoVs
genera that infect mostly mammals [23, 24].
As it is shown in Fig. 1, SARS-CoV-2 from β-CoV
genus, similar to other members of the Coronaviridae
family, is an enveloped virus with the positive single-
stranded RNA genome of around 26–32 Kb in size. It is
methylated at 5′ and has a poly-A tail at 3′. The viral
genome produces mRNAs that translate into four viral
structural proteins, including the spike glycoprotein (S),
membrane protein (M), nucleocapsid protein (N) and
envelope protein (E). The virus uses the host protein
synthesis apparatus to produce its proteins during the
replication [25].
Glycoprotein S detects and binds to the host cell re-
ceptor on the membrane surface and is responsible for
the virus entering the cell through endocytosis. It deter-
mines the invasive tissue and the host species due to its
binding properties, which is determined by its receptor-
binding domain (RBD). RBD or C-domain is responsible
for identifying the host cell receptor and attaching the
virus to it. Glycoprotein M is involved in the formation
of envelope and assembly of the virus. The basic
phosphoprotein N associates genomic RNA with the
capsid [26]. During synthesis, newly synthesized viral
polypeptides are checked by host chaperones such as
calnexin and HSPs to ensure proper protein folding. For
final maturity, the immature viral proteins in the ER are
transported to the Golgi chamber, where the viral parti-
cles assemble to form complete viruses [27].
As mentioned, glycoprotein S plays an important role
in the entry of SARS-CoV-2 into host cells through
ACE2 receptor located in the plasma membrane of host
cells [25]. GRP78 (Glucose-regulated protein 78) or
HSPA5 (Heat Shock Protein Family A (Hsp70) Member
5) is another receptor for spike glycoprotein on the cell
surface and can mediate virus entry. This protein is also
known as the immunoglobulin binding protein (BiP),
which is an ER chaperone. Upon viral infection, GRP78
is upregulated, and translocated to the cell membrane
where it is subjected to be recognized by the SARS-
CoV-2 spike [28, 29] (Fig. 2).
Binding of the virus to cells occurs by binding of the
viral spike protein to ACE2. The virus can then use
endocytosis or fusion with the surface membrane to
enter the host cells. In both cases, the ACE2-binding
spike must be broken (“activated”) by specific protease
of 3CLpro (3C-like serine protease) or viral PLpro
Fig. 2 [7]: SARS-CoV-2 and molecular chaperones. a GRP78 or HSPA5 can be part of the ACE2-receptor complex recognized by the SARS-CoV-2
and can modulate virus entry. b ACE2-binding spike must be broken by specific proteases of 3CLpro (3C-like serine protease) or viral PLpro
(papain-like cysteine protease) to allow the spike fusion domains to function. 3CLpro, also induces apoptosis thought caspase’s pathways. c
Molecular chaperones, such as GRP78 and GRP94, participate in the folding of SARS-CoV-2 proteins. RdRp (RNA-dependentRNA polymerase)
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(papain-like cysteine protease) to allow the spike fusion
domains to function. 3CLpro, also induce apoptosis
thought caspase’s pathway, causing a significant increase
in reactive oxygen species (ROS) [30, 31]. In endosomes,
the spike is broken down by Cathepsin L, then the viral
membrane combines with the endocrine membrane [32].
At the cell surface, the spike is broken down by other
proteases, mainly TMPRSS2 (transmembrane protease,
serine 2), to ensure fusion of the virus membrane and
host cell [33]. After fusion, the genomic and protein
content of SARS-CoV-2 is transferred to the cytosol and
the virus begins its replication cycle. The negative-sense
genomic RNAs is synthesized by using the positive-
sensegenome as a template and then translated by the
host ribosome into the structural and accessory proteins
[34].
Like other viruses, SARCE-Cov-2 is obligate intracellu-
lar parasite, and its replication requires host cell func-
tions. CoVs rely absolutely on the protein synthesis
machinery of the host cell [35]. Once a virus enters the
cell, the RNA of the viral genome is translated to pro-
duce the viral proteins needed for subsequent RNA rep-
lication and transcription. Because genomic and
subgenomic CoV mRNAs have a 5′ cap structure, most
CoV mRNAs are thought to undergo cap-dependent
translation using eIF4F. eIF4F and the 43S preinitiation
complex access the 5′-end of the capped viral genome
and the 43S preinitiation complex scans the 5′ UTR.
The 80S complex is assembled at the translation initi-
ation codon and protein synthesis starts and proceeds
until the first termination codon is encountered and the
ribosome dissociates from its mRNA template, resulting
in polyprotein (pp) 1a [35–37]. Production of pp1ab
(encoded by both ORF1a and ORF1b) requires a − 1
ribosomal frameshift before the translation stop codon is
reached. This frameshift has been shown to occur in the
overlap region between ORFs 1a and 1b. Viral proteins
encoded downstream of ORFs 1a and 1b are not synthe-
sized from the genome RNA but from a set of 5′-capped
subgenomic mRNAs that carry the respective ORFs in
their 5′-terminal regions. The two replicase polyproteins
translated from ORFs 1a and 1b undergo proteolytic
cleavage via viral-encoded proteinases encoded in ORF1a
to generate 15–16 mature nonstructural proteins,
termed nsp1 to nsp16. All of these nsps, except for nsp1.
and nsp2 are considered essential for transcription and
replication of CoV RNA [35, 36].
Rapid replication of the virus in the host cell is a sign
of successful synthesis of its proteins in the rough endo-
plasmic reticulum, which is guaranteed by the use of ER
molecular chaperones. Molecular chaperones, such as
GRP78 and GRP94, BiP (binding immunoglobulin pro-
tein), PDI (protein disulfide isomerase), calreticulin, and
calnexin participate in the folding of SARS-CoV-2
proteins, to ensure proper folding, sugar chain modifica-
tion, and complex formation [38, 39]. BiP chaperones
are attached to the ATF6 (activated transcription factor
6), IRE1 (inositol requiring kinase-1), and PERK (PKR-
like ER related kinase) [29, 40]. The chaperone, also
counteract the effect of the stress of the host cell caused
by viral infection. However, high and uncontrolled ex-
pression of viral proteins increases the percentage of un-
folded and misfolded proteins in ER lumen which results
in induction of ER stress. ER stress dissociates BiP from
ATF6, IRE1, and PERK leading to the activation of these
membrane proteins and to an adaptive cellular response
known as UPR. Free ATF6 is transported from the ER to
the Golgi, where the amino portion of its cytoplasmic
terminal is cleaved and converted into a factor transcrip-
tion [41]. Then, it moves to the nucleus and induces
transcription of genes involved in UPR, such as those
encoding ER chaperones [42, 43]. After forming homo-
multimer, IRE1 and PERK are autophosphorylated. IRE1
acts as an RNase and splices X-box binding protein-1
(XBP-1) mRNA which is translated into XBP-1. XBP-1
is a transcription factor that induces genes involved in
the progression of the UPR and also mitogen-activated
protein (MAP) kinases such as c-jun N-terminal kinase
(JNK) [44]. PERK phosphorylates and inactivates
eukaryotic initiation factor 2α (eIF2α), which suppresses
protein synthesis and prevents from unfolded protein ac-
cumulation [45]. Therefore, UPR is a cell-protecting
process managed by ER molecular chaperones, suppress-
ing protein translation, and activating degradation of
misfolded proteins. PERK also induces ATF4, which ac-
tivates the transcription factor C/EBP homologous pro-
tein (CHOP). CHOP downregulates anti-apoptotic
molecule of Bcl-2 which leads to apoptotic cell death. In
ER stress, intracellular Ca2+ homeostasis is disrupted
and Ca2+ released into the cytoplasm [46]. Calcium infil-
tration into the mitochondria makes release of cyto-
chrome C, caspases 3 and 9 activation leading to
apoptosis and cell death [47]. Therefore, in viral invasion
and excessive load of unfolded or misfolded proteins,
the UPR and ER-associated degradation (ERAD) pre-
vents severe events in the body, and if necessary, end cell
life. However, UPR may be useful for viral infection be-
cause ER chaperones increase and correct the folding of
viral proteins, or may be harmful because increase in ex-
pression of agents involved in protein degradation may
destroy viral proteins.
Patients infected with SARS-CoV2 have shown apop-
tosis in pneumocytes, T and B lymphocytes, and mono-
cytes in the lungs, spleen, and lymph nodes. Thus, early
in the course of the disease, they develop lymphopenia
due to a decrease in the number of CD4+ and CD8+ T
cells. ER stress plays an important role in the occurrence
of these events [48, 49].
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ACE2 and ER Stress
ACE2 is found in a variety of cells and tissues, including
the kidneys, lungs, heart, blood vessels, liver, and gastro-
intestinal tract and play an important role in preventing
inflammation and tissue fibrosis. It is also abundant in
the epithelium lining of the lungs, mouth and nose [50].
Previous studies have indicated that ACE2-mediated sig-
naling reduces the effects of ER stress, so that, stimula-
tion of ACE2 by agonists suppresses apoptosis mediated
by ER stress [51]. Thus, occupying ACE2 by glycoprotein
S may intensify ER stress via inhibiting ACE2 signaling.
Increased ER stress may be one of the causes of pulmon-
ary fibrosis in COVID 19 [52].
Comfortable and natural breathing in the lungs is due
to the presence of surfactant that produced by type 2
pneumocytes and composed of phospholipids and pul-
monary surfactant proteins of A, B, C, and D. ACE2 is
highly expressed in type 2 pneumocytes, therefore, these
cells are highly susceptible to infection and destruction
by SARS-CoV-2, which is associated with decreased pul-
monary surfactant and pneumonia [53, 54]. For this rea-
son, surfactant replacement therapy was considered as
one of the treatment suggestions to help improve the re-
spiratory status of Covid 19 patients [55]. Moreover, sur-
factant protein C (SP-C) contains a chaperone-like of
BRICHOS, which prevent SP-C from forming amyloid-
like fibrils (Dolfe et al., 2016). In ER, BRICHOS of
proSP-C binds to other SP-C peptides and prevent them
from forming amyloid via inducing α-helix formation
[56]. Decreased ACE2 signaling in COVID 19, and sub-
sequently, increased ER stress and overt protein re-
sponse, may disrupt such chaperone-like processes,
causing fibrosis through SP-C accumulation in the lung.
The anti-inflammatory properties of ACE2 have been
attributed to the inhibition of AngII (angiotensin II) pro-
duction by increasing the conversion of AngI to other
molecules, including Ang (1–9) to Ang (1–7). Ang (1–
7), unlike AngII, is a vasodilator with anti-inflammatory
properties, which acts through Mas receptors [25].
Therefore, ACE2 can be considered as a negative regula-
tor of the local renin-angiotensin system in the lung,
and its occupation in lungs by SARS-CoV-2 disrupts
AngII tissue homeostasis, leading to inflammation and
fibrosis. Moreover, increased AngII levels in the lungs
constrict the alveoli, causing decreased O2 / CO2 ex-
change and decreased O2 levels in the blood. Decreased
blood O2 level is life-threatening in patients with Covid
19 and necessitate the use of a ventilator apparatus [57].
Dipeptidyl peptidase 4 (DPP4) is another receptor for
SARS-CoV-2, that its potency is enhanced by attaching
to BiP. BiP is upregulated in ER stress. Thus, in SARS-
CoV-2 infection, an increase in BiP molecules and its
binding to DPP4 intensify the infection in patients with
COVID-19 [58].
SARS-COV-2, and Immune and Autoimmune
Reactions
The most common fatal complication in COVID-19 pa-
tients is pneumonia and excessive systemic inflammation
in which serum levels of pro-inflammatory cytokines
such as IL-2, IL-6, IL-7, IL-10, MCP1, MIP1A, and
TNFα increase [59]. High levels of inflammatory media-
tors in genetically predisposed individuals are due to
over-stimulation of the immune system and over-
activation of local macrophages by the corona virus. Ac-
tivated macrophages, as the main immune cells in the
lung parenchyma, may have an important role in the
pathophysiology of SARS-CoV-2-induced acute respira-
tory distress syndrome (ARDS) [60]. Interestingly, al-
though ACE2 is a membrane receptor for SARS-CoV-2
infection, it is also present in the bloodstream as a sol-
uble protein and can bind to and inhibit SARS-CoV-2.
Formation of SARS-CoV-2-ACE2 complex may stimu-
late immune system to produce antibodies [61].
Evidence from clinical trials has shown the presence of
autoimmune reactions in COVID-19 patients and a
strong association between this autoimmunity and se-
vere SARS-CoV-2 infection [62]. Anti-nuclear autoanti-
bodies (ANA) [63], Lupus anti-coagulant, Anti-SSA
(anti–Sjögren’s-syndrome-related antigen A) autoanti-
bodies, anti-cardiolipin (aCL) [64] and anti-β2 glycopro-
tein 1 (aβ2GP1) autoantibodies are autoimmune markers
that have been detected in COVID-19 patients [65]. Cui
et al. detected high blood factor VIII (FVIII), along with
the last two antibodies, in COVID-19 patients, indicating
hypercoagulation in them [66]. Bastard et al. reported
the present of IgG auto-antibodies against type I IFNs in
COVID-19 patients,, which destroy the ability of type I
IFNs to prevent SARS-CoV-2 infection in vitro [67].
The melanoma differentiation-associated protein 5
(MDA5) is a receptor capable of detecting different type
of RNA molecules [68]. Anti-MDA5 autoantibodies are
associated with a rare disease of amyopathic dermato-
myositis [69]. De Lorenzis et al. found anti-MDA5 anti-
body in SARS-CoV-2-infected patients [70].
Table 1 shows the types of autoantibodies found in
COVID-19 patients, which increases the likelihood of
additional antibodies. It also shows autoimmune disease/
syndromes that are secondary to COVID-19 infection
The production of such autoantibodies, in addition to
being life-threatening, may be the cause of the variety of
pathophysiological manifestations of the disease among
individuals. The production of such antibodies, in
addition to being life-threatening, may explain the var-
iety of pathophysiological manifestations in COVID-19
patients.
Another case of autoimmunity phenomena may be
due to molecular mimicry or immunological cross-
reactivity in the immune response between viral and
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human molecules. The existence of such similarities may
make it difficult for individuals to prepare and produce a
vaccine and prescribe it, as autoimmune conditions may
develop [71]. For example, in their bioinformatics study,
Gammazza et al. showed the presence of the shared pep-
tides between 17 human chaperones and viral proteins
[72]. They stated that the cellular stress caused by
SARS-CoV-2 could increase the expression of these
chaperones and the possibility of their transfer from the
intracellular site to the plasma membraneو that may
stimulate the autoimmune reaction after detection by
the immune system. For example, HSP60, HSP70, and
HSP90 have been shown to be chaperones produced
under stress and localized in plasma membranes [73].
Chaperone Therapy
Although COVID-19 patients are treated with glucocor-
ticoids to modulate the cytokine storm caused by severe
immune stimulation by SARS-CoV-2, in some cases it is
not sufficient. Due to the possible role of chaperones in
the survival and infection of SARS-CoV-2, today
chaperone therapy has attracted the attention of re-
searchers to treat COVID-19 disease. Drug chaperones
have been suggested to suppress cell dysfunction, in-
flammation, and apoptosis by preventing the accumula-
tion of unfold proteins in ER and reducing ER stress,
and have been proposed as a promising therapeutic
strategy in COVID-19 [40]. However, this method of
treatment is debatable. If the use of chaperone supple-
ments helps to produce high-quality viral proteins as
well as the stabilization of more compatible mutations, it
causes the virus to multiply and survive in the patient;
but if it stabilizes mutations that lead to disruption of
the assembly of the virus and a reduction in the quality
of its protein antennae, thereby reducing its infectivity,
then it will be effective in treating COVID-19. For ex-
ample, tauroursodeoxycholic acid (TUDCA) induces
proper folding of functional proteins and improves pro-
teostasis in virus-infected cells via a reduction in inflam-
mation and cell apoptosis. The mentioned mechanism
includes the suppression of BiP dissociation from PERK,
and inhibition of eIF2α phosphorylation, and ATF4-
CHOP activation. Reduced ATF4-CHOP increases the
expression of anti-apoptotic BCL-2 and decreases the
expression of pro-apoptotic Bax, and then suppression
of caspase-3 [40]. The role of the drug chaperon of
TUDCA against some acute diseases has been studied in
cell cultures and animal models [74–76]. Another drug
that can be considered in reducing the inflammatory ef-
fects of the coronavirus is the HSP60 inhibitor [77].
HSP60 is a vital chaperone for mitochondrial proteosta-
sis that play a significant role in energy hemostasis
through regulation of mitochondrial enzymes involved
in oxidative phosphorylation. Under pathophysiological
conditions the HSP60 can leave the mitochondria and
excreted from the cell into circulation. In the blood
stream, it can induce inflammatory response through
binding to the Toll-like receptors, activating the NF-κB
pathway and stimulating the proinflammatory cytokine
release [77]. Jakovac et al. stated that after primary tissue
damage by SARS-CoV-2, HSP60 could be released from
damaged cells into the bloodstream [77]. Therefore,
Table 1 List of autoimmune diseases and autoantibodies associated with SARS-CoV-2 infection
Autoimmune disorder secondary to SARS-CoV-2 infection Autoantibodies detected in COVID-19 patients
Antiphospholipid syndrome Antiphosphatidylserine IgM/IgG
Immune thrombocytopaenic purpura Anti-SSA autoantibody
Guillain-Barré syndrome Anti-globulin antibodies
Cold agglutinin disease & autoimmune Anti-nuclear antibodies (ANA)
Systemic lupus erythematosus (SLE) Anti-cardiolipin (aCL) antibodies
Miler Fisher Syndrome (MFS) Anti-MDA5 antibodies
Kawasaki disease Anti-β2 glycoprotein 1 antibodies
NMDA-receptor encephalitis LAC –lupus anticoagulant
Subacute thyroiditis Antiprothrombin IgM
Graves’ disease Anti-GD1b antibodies
Sarcoidosis Anti-CCP antibodies
Myasthenia gravis Anti-heparin PF4 complex antibody
Hemolytic anemia Antiannexin V IgM/IgG
Neuromyelitis optica pANCA AND cANCA
Large vessel vasculitis & thrombosis
Type I diabetes
Psoriasis
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HSP60 inhibitors with potent immunosuppressive activ-
ity such as misoribine may be useful in inhibiting viral
function, especially in patients suffering from hyperten-
sion and infected with SARS-CoV-2.
Conclusions
Similar to the process of host protein synthesis, viruses
typically exploit host chaperones to support viral tran-
scription and replication. Such utilization of the host
protection system helps the viruses to stabilize their mu-
tations as well as the compatibility and persistence of
the infection. Therefore, recognizing and then inhibiting
the associated pathogenic chaperone and other factors in
the proteostasis network that protects the viral life cycle
and infection should be considered in the treatment of
COVID19. Another contributing factor to SARS-CoV-2
infection is the similarity of the epitope to those in host.
Such a phenomenon makes it difficult to produce a vac-
cine against SARS-CoV-2 and makes people suspicious
of its use.
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